19/05/2026 UCB announced week 16 data from the BE BOLD study in PsA UCB announced week 16 data from the BE BOLD study in PsA (Ref) UCB announced data from the Phase 3, BE BOLD/ NCT06624228 study which compared the efficacy of BIMZELX®(bimekizumab; Anti-IL-17A and anti-IL-17F) versus SKYRIZI®(risankizumab; Anti-IL-23) after 16 weeks of treatment in participants with active psoriatic arthritis (PsA). The study met its primary endpoint of belimumab superiority in ACR50 at Week 1